SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-042563
Filing Date
2020-09-04
Accepted
2020-09-03 19:00:33
Documents
12
Period of Report
2020-09-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K stro-8k_20200903.htm   iXBRL 8-K 36401
  Complete submission text file 0001564590-20-042563.txt   170294

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA stro-20200903.xsd EX-101.SCH 5776
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE stro-20200903_lab.xml EX-101.LAB 20210
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stro-20200903_pre.xml EX-101.PRE 12084
5 EXTRACTED XBRL INSTANCE DOCUMENT stro-8k_20200903_htm.xml XML 3679
Mailing Address 310 UTAH AVE., SUITE 150 SOUTH SAN FRANCISCO CA 94080
Business Address 310 UTAH AVE., SUITE 150 SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

IRS No.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 201160320
SIC: 2836 Biological Products, (No Diagnostic Substances)